Abstract 398P
Background
Projections of the national burden of cancer are essential for planning cancer control programs and anticipating future cancer burden on the health service. This study aims to evaluate the current trend and project cancer incidences of the top five cancers in Uganda: Kaposi sarcoma (KS), cervical, breast, prostate, and Non-Hodgkin’s lymphoma (NHL).
Methods
Projections were based on incidence data obtained from the population-based Kampala cancer registry for the 2000-2014 periods, and population data was acquired from the National Bureau of Statistics. Joinpoint software was used to study the trend and presented results using age-specific rates, age-standardized rates, crude rates, and annual percentage change. Two methods were applied to project incidence up to 2029. First, we extrapolated results of the recent trend from joinpoint model to estimate future incidence with the assumption that coefficient estimates will remain constant. Second, we fitted the age-period-cohort model using Nordpred R-package, which accounts for age, period-birth cohort effects, rates were standardized using the standard world population (WHO 2000-2025).
Results
Breast, cervical, and prostate cancer incidences are forecasted to increase by 2029. Their new cases are expected to increase by 200.5%, 98.7% and 184.3 % respectively with the ASRs (per 100,000) escalating from 30.9, 51.9, 44.9 in 2000-2004 to 40.8, 52.7, 64.3 in 2025-2029. Incidences of KS and NHL are, on the other hand, anticipated to decrease for both males and females with both projection methods showing the same results. From 2000 to 2029, the ASR is expected to decrease markedly from 30.3 to 6.1 for KS and from 7.3 to 2.4 for NHL. The reduction in the number of cases is predominantly attributed to the change in their risk. The incidence rates were at peak among people aged from 65 to 74 for breast, cervical, prostate cancers, and those above 75 years for KS and NHL in the observed period. These patterns are expected to remain unchanged in the next decade.
Conclusions
Future research should be directed towards strategies to control the growing burden of breast, cervical, and prostate cancers since their incidence rates are forecasted to increase in the future according to our study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asasira Judith.
Funding
“International Cooperation & Education Program (#NCCRI•NCCI 52210-52211, 2019)” of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract